Business Wire

MD-IONQ

22.7.2024 14:01:26 CEST | Business Wire | Press release

Share
IonQ Unveils Accelerated Roadmap and New Technical Milestones to Propel Commercial Quantum Advantage Forward

IonQ (NYSE: IONQ), a leader in the quantum computing industry, recently unveiled expanded and accelerated 2025 technical milestones during an exclusive webinar hosted by CEO Peter Chapman, SVP of Engineering & Technology Dean Kassmann, and CMO Margaret Arakawa. IonQ established why it is the only quantum computing company designing and building best-in-class quantum computers that meet the requirements of performance, scalability, and enterprise-grade solutions that are critical for delivering unparalleled commercial advantage to customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722272052/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IonQ's three-pillar technology strategy to accelerate commercial advantage. (Graphic: Business Wire)

“It is imperative that we address performance, scale, and enterprise-grade quantum solutions simultaneously to achieve commercial advantage,” said Peter Chapman, President and CEO of IonQ. “Working to operationalize all three commercial advantage pillars is an industry-first that sets us apart. While other companies may hyperfocus on a single dimension, we focus on the complete picture, to ensure our quantum computing solutions are best-in-class and provide incomparable value to our customers.”

“Based on market demand, we’ve embarked on a path that no other commercial quantum computing company is taking, and we are committed to accelerating our quantum computing strategy as demonstrated by these ambitious goals,” said Dean Kassmann, SVP of Engineering & Technology at IonQ. “Our unique approach combines high performance single core operation, multi-core parallelism, modularity, photonic interconnects, novel technology, and systems engineering to deliver highly performant, scalable, and enterprise-grade quantum computers that drive meaningful advancements across various industries.”

Performance: Driving Efficiency and Unparalleled Flexibility

Performance improvements are core to IonQ’s technical roadmap, and the path toward meeting IonQ’s aggressive performance targets is clear. Native gate fidelity, architectural design decisions, and error correction will serve as levers to achieve these goals. IonQ is driving to improve native two-qubit gate performance to greater than three 9’s (>99.9%) in 2025, with further gains – fueled by the move to barium qubits – expected the following year. Performance improvements are also expected from highly efficient realizations of quantum algorithms that are enabled by IonQ’s low-shuttling, high-connectivity architectures. Lastly, the combination of high native gate fidelity and high connectivity provides unparalleled flexibility for implementing error correction and reducing time to solution. With this updated quantum architecture, IonQ expects to reach five 9’s (99.999%) in logical two-qubit gate fidelity by the end of 2025, opening up new application performance capabilities.

Scale: Architecture that Enables Expansive Growth

IonQ is pursuing scale in tandem with performance. IonQ’s north star is scalability at high performance, and modularity is a critical component of this strategy. IonQ’s approach to scale relies on making engineering and architectural decisions that support performance at large qubit counts. In addition, IonQ’s strategy for scaling takes advantage of multicore operation and photonically interconnected systems. Connecting multiple QPUs and quantum systems with photonic interconnects will enable IonQ to target 1000s of physical qubits in the future. These higher qubit counts will unlock new problem spaces and enable developers and researchers to tackle increasingly complex problems.

Enterprise-Grade: Meeting Real-World Needs

IonQ’s enterprise-grade approach readies its quantum systems for deployment across various sectors, focusing on manufacturability, deployability, and customer applications at scale. IonQ has already formed successful partnerships with organizations like the Naval Research Laboratory (NRL), Airbus, and Deutsches Elektronen-Synchrotron (DESY) – an internationally renowned center of fundamental research – as they focus on optimization problems and quantum chemistry and other important real-world applications. Additionally, IonQ is exploring a growing number of quantum algorithms across fields such as AI, financial services, and cybersecurity, reinforcing its commitment to real-world quantum technology applications.

Currently, IonQ operates two quantum data centers—one at its headquarters in College Park, Maryland, and another in Seattle, Washington, which the company opened earlier this year. Later this year, IonQ will expand its footprint by bringing its quantum data center in Basel, Switzerland, online. All of these locations are dedicated to supporting the needs of IonQ’s customers.

This momentum underscores IonQ's leadership in the quantum computing industry and robust industry demand. IonQ's enterprise strategy and expanding infrastructure highlight its dedication to unlocking commercial advantage by collaborating with industry leaders and making cutting-edge, well-balanced, quantum technology available ahead of schedule.

To learn more about IonQ and its latest system news and business developments, visit https://ionq.com/.

About IonQ

IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “accelerate,” “advance,” “dedicate,” “deploy,” “drive,” “enable,” “expand,” “expect,” “improve,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial advantage in the future, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, the effect of increased availability of customer support functions and enterprise-grade solutions, IonQ’s quantum computing capabilities and plans, access to IonQ’s quantum computers, increases in algorithmic qubit achievement, and the scalability, performance, and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates, including development of competing technologies; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722272052/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release

Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic

An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal

Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release

Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve

Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release

The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value

Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release

Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye